Dextera Biosciences
Kyle Landgraf is a seasoned biochemist and molecular biophysicist with extensive experience in drug discovery and development in the biopharmaceutical industry. Currently serving as Senior Director of Discovery Research at Dextera Biosciences since August 2021, Landgraf previously held the position of Director of Discovery Research at Reflexion Pharmaceuticals, where the focus was on D-protein drug development. Earlier roles include Senior Scientist positions at AvidBiotics and Reflexion Pharmaceuticals, consulting at Xyphos Biosciences, and a Postdoctoral Research Fellowship at Genentech. Landgraf's academic background includes a Ph.D. in Biochemistry and Molecular Biophysics from the University of Colorado Boulder and a B.S. from the University of Arizona. Major contributions include the development of therapeutics platforms and innovations in CAR-T cell therapies.
This person is not in any teams
This person is not in any offices
Dextera Biosciences
Dextera Biosciences is developing a new category of drugs, Synthetic D-Proteins, to overcome the limitations of current drug modalities. Synthetic D-Proteins exhibit antibody-like specificity to a single therapeutic target but with the broad distribution of small molecules, all while being otherwise “invisible” to the rest of the body. The consequences are that we can deliver sustained antibody-like activity specifically to interstitial targets, enable oral delivery with complete metabolic stability, and extend therapeutic durability with no immunogenicity. We are focusing on debilitating diseases where significant unmet need remains due to the limitations of current drugs.